We are live on ! Find out more
DMIIU

Drugs Made In America Acquisition II Corp Unit
DMIIU

14 hedge funds and large institutions have $43.5M invested in Drugs Made In America Acquisition II Corp Unit in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

14.14% less ownership

Funds ownership: 22.64% → 8.5% (-14%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

53% less funds holding

Funds holding: 30 → 14 (-16)

63% less capital invested

Capital invested by funds: $116M → $43.5M (-$72.6M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 17

Holders
14
Holders Change
-16
Holders Change %
-53.33%
% of All Funds
0.17%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
1
Increased
1
Reduced
4
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
+$2.11M
2
RC
Rangeley Capital
Connecticut
+$232K

Top Sellers

Rank Fund Capital Flow
1
MI
MMCAP International
Cayman Islands
-$27M
2
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$20M
3
HCM
Heights Capital Management
California
-$5.19M
4
Millennium Management
Millennium Management
New York
-$5.01M
5
RCM
Rivernorth Capital Management
Florida
-$4.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
LP
1
LMR Partners
United Kingdom
$20.1M – – –
WCMNY
2
Westchester Capital Management (New York)
New York
$5.05M – – –
TAL
3
TIG Advisors LLC
New York
$5.02M – – –
BCM
4
BlueCrest Capital Management
Jersey
$2.51M – – –
Verition Fund Management
5
Verition Fund Management
Connecticut
$2.51M – – –
KC
6
Kepos Capital
New York
$2.11M +$2.11M +210,000 New
CS
7
Clear Street
New York
$1.67M -$702K -69,790 -30%
LGM
8
L1 Global Manager
$1M – – –
RAM
9
Readystate Asset Management
Illinois
$1M – – –
Walleye Capital
10
Walleye Capital
New York
$1M – – –
HF
11
HRT Financial
New York
$1M -$368K -36,560 -27%
RC
12
Rangeley Capital
Connecticut
$327K +$232K +23,061 +71%
RCM
13
Robinson Capital Management
Michigan
$151K -$101K -10,000 -40%
UBS Group
14
UBS Group
Switzerland
$17.7K -$922K -91,707 -98%
MI
15
MMCAP International
Cayman Islands
– -$27M -2,700,000 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
16
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$20M -2,000,000 Closed
HCM
17
Heights Capital Management
California
– -$5.19M -519,400 Closed
Millennium Management
18
Millennium Management
New York
– -$5.01M -500,000 Closed
RCM
19
Rivernorth Capital Management
Florida
– -$4.01M -400,000 Closed
SCM
20
Steadfast Capital Management
New York
– -$3M -300,000 Closed
GCIA
21
Gabelli & Co Investment Advisers
New York
– -$1.8M -179,500 Closed
GF
22
Gabelli Funds
New York
– -$1.62M -161,400 Closed
SSA
23
Schonfeld Strategic Advisors
New York
– -$1.14M -113,527 Closed
CC
24
Centiva Capital
New York
– -$1M -100,000 Closed
Parallax Volatility Advisers
25
Parallax Volatility Advisers
California
– -$892K -89,079 Closed
1
2

DMIIU Hedge Fund Activity: Q1 2026 in Review

14 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition II Corp Unit (DMIIU) for Q1 2026, worth a combined $43.5M — down 63% from $116M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of DMIIU and 1 opened new positions — a net loss of 16 holders — while 4 trimmed existing stakes and 1 added.

The largest buyer was Kepos Capital, opening a new position worth an estimated $2.11M. The largest seller was MMCAP International, exiting entirely with an estimated $27M sold.

  • 14 institutional investors held Drugs Made In America Acquisition II Corp Unit (DMIIU) as of Q1 2026, down from 30 in Q4 2025.
  • Funds reported $43.5M of Drugs Made In America Acquisition II Corp Unit stock for Q1 2026, down 63% quarter-over-quarter.
  • 1 fund opened new Drugs Made In America Acquisition II Corp Unit positions in Q1 2026 and 17 closed out, a net change of -16 holders.
  • The largest Drugs Made In America Acquisition II Corp Unit buyer in Q1 2026 was Kepos Capital, an estimated $2.11M added.
  • The largest Drugs Made In America Acquisition II Corp Unit seller in Q1 2026 was MMCAP International, an estimated $27M sold.

Based on aggregated 13F filings for Q1 2026.